Preclinical Characterization of Efficacy and Pharmacodynamic Properties of Finotonlimab, a Humanized Anti-PD-1 Monoclonal Antibody
<b>Background/Objectives:</b> Finotonlimab (SCTI10A) is a humanized anti-PD-1 antibody tested in Phase III trials for several solid tumor types. <b>Methods</b>: This study characterized the in vitro and in vivo efficacy, Fc-mediated effector function, and non-clinical PK/PD properties of finotonlima...
Zapisane w:
| Główni autorzy: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
MDPI AG
2025-03-01
|
| Seria: | Pharmaceuticals |
| Hasła przedmiotowe: | |
| Dostęp online: | https://www.mdpi.com/1424-8247/18/3/395 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|
